Savant Capital LLC Has $3.14 Million Stock Holdings in Astrazeneca Plc $AZN

Savant Capital LLC lessened its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 66.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 17,864 shares of the company’s stock after selling 35,838 shares during the quarter. Savant Capital LLC’s holdings in Astrazeneca were worth $3,135,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of AZN. Triumph Capital Management acquired a new stake in Astrazeneca during the 3rd quarter worth $25,000. Bangor Savings Bank grew its holdings in Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares during the period. Eagle Bay Advisors LLC acquired a new stake in Astrazeneca during the 4th quarter worth $30,000. YANKCOM Partnership acquired a new stake in Astrazeneca during the 4th quarter worth $31,000. Finally, TFC Financial Management Inc. grew its holdings in Astrazeneca by 3,350.0% during the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after acquiring an additional 335 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Thursday, May 14th. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Thursday, May 21st. Finally, Barclays raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Trading Up 0.1%

Shares of NYSE AZN opened at $185.50 on Friday. The company’s fifty day moving average is $191.27 and its 200-day moving average is $183.97. The stock has a market cap of $287.70 billion, a price-to-earnings ratio of 27.85, a P/E/G ratio of 1.48 and a beta of 0.26. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Equities research analysts predict that Astrazeneca Plc will post 10.26 EPS for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.